Mabion Wins Best of Industry Insights Award for Biologics Outsourcing Article in Outsourced Pharma Best Of 2024
- Mabion’s article, Four Steps to Identifying the CDMO Proposal Worth Signing, won Best of Industry Insights in the Biologics Outsourcing category of the Outsourced Pharma Best Of 2024 awards, recognizing the company’s expertise in biologic drug development.
- Navigating the technical and financial aspects of CDMO selection requires experience, which can be challenging for new companies on biotech market. Investing time in learning how to evaluate service providor proposals can lead to better decision-making and long-term benefits for biologics development.
Mabion is honored to announce that our article, Four Steps to Identifying the CDMO Proposal Worth Signing, has been awarded Best of Industry Insights in the Biologics Outsourcing category of the Outsourced Pharma Best Of 2024 awards. It is a tribute to our team’s expertise and commitment to providing valuable industry information and showcasing our capabilities in biologic drug development.
Authored by Bartłomiej Czubek, Director of Business Development, and Anna Czubatka-Bieńkowska, Head of the Project Management Division, the article provides a strategic framework for biotech companies navigating the complex process of selecting a Contract Development and Manufacturing Organization. The piece outlines key insights into evaluating CDMO proposals, identifying potential risks, and recognizing the hallmarks of a reliable manufacturing partner.
Recognize the Red and Green Flags during biologics outsourcing selection
Selecting the right CDMO is a crucial step in the biologics development journey. The article emphasizes the importance of understanding the proposal process, recognizing red flags such as unrealistic timelines and ambiguous cost structures, and prioritizing green flags such as transparency, flexibility, and a commitment to quality. By equipping biotech companies with the knowledge to assess CDMO proposals critically, the article aims to help sponsors avoid costly setbacks and ensure a successful DS manufacturing partnership.
Read the full winning article here.
Mabion extends its congratulations to all award winners and expresses gratitude to Outsourced Pharma for recognizing our contributions to the biologics outsourcing industry.
Prepared by:
Sources and further reading
- Czubek B., Czubatka-Bieńkowska A. (2024). Four Steps to Identifying the CDMO Proposal Worth Signing. Outsourced Pharma. Link: https://www.outsourcedpharma.com/doc/four-steps-to-identifying-the-cdmo-proposal-worth-signing-0001